Approval Positions Roxadustat As Japan HIF-PHI Pioneer
Executive Summary
The latest batch of product approvals in Japan positions Astellas’s roxadustat as the pioneer in the country’s potentially large HIF-PH inhibitor market in anemia, while Takeda and Meiji Seika see other important approvals and the first biosimilar teriparatide receives a nod.
You may also be interested in...
Clear Path For AstraZeneca’s Roxadustat After Reassuring Safety Data
Strong results in non-dialysis patients are a particular boost for AZ and its partner, Fibrogen.
Hypoxia Nobel Prize Winners: How Biopharma Is Using Their Research
Academic research has once again demonstrated itself to the oxygen of inspiration for industry drug innovation, including a blockbuster-in-waiting
Vadadustat Emerges As Japan HIF-PHI Contender With First Filing Globally
Competition intensifies in novel anemia therapy space in Japan with first filing globally for Akebia/Mitsubishi Tanabe’s contender vadadustat, which could see its first launch worldwide in the country.